摘要
目的:分析CRM1基因在骨肉瘤手术标本中的表达及其预后价值。方法:采用蛋白质印迹法检测57例骨肉瘤手术标本和5例正常软骨组织标本中的CRM1基因表达,并进一步分析其对于骨肉瘤患者的预后价值。结果:CRM1基因在骨肉瘤组织中的表达显著高于在正常组织中的表达;CRM1基因高表达和血清碱性磷酸酶水平升高显著相关(P=0.001),但和血清乳酸脱氢酶水平升高无关(P=0.065)。单因素分析表明,CRM1基因高表达和肿瘤大小以及病理学分级之间显著相关(P值分别为0.014和0.003),而和其他临床病理特点无关。Kap-lan-Meier生存分析表明,CRM1基因高表达对于骨肉瘤患者的无进展生存期和总生存期差异有统计学意义(P值分别为0.016和0.008)。而多因素分析表明,CRM1基因高表达对于骨肉瘤患者是一个独立预后因素(95%CI,1.27～5.39)。结论:CRM1基因高表达与骨肉瘤患者的血清碱性磷酸酶水平升高、肿瘤大小以及病理学分级显著相关;是骨肉瘤的独立预后因素。
OBJECTIVE： To investigate the expression of CRM1 in osteosarcoma and normal cartilage tissues. METHODS： Western blot was used to investigae the expression of CRM1 in 57 cases of osteosarcoma compared with 5 cases of normal tissues. RESULTS： The expression of CRM1 was significantly higher in osteosarcoma than that in normal tissues. The high expression of CRM1 was significantly associated with the increased serum level of alkaline phosphatase （P = 0. 001） but did not associate with that of lactate dehydrogenase （P= 0. 065）. In univariate analysis, a significant association between CRM1 expression and tumor size （P=0. 014） as well as histological grade （P=0. 003） was observed, while high CRM1 expression was not correlated with the other clinieopathotogical parameters. In Kaplan-Meier survival analysis, the high CRM1 expression was a significant prognostic indicator for progression-free survival （P=0. 016） as well as overall survival （P=0. 008）. Mult- ivariate analysis demonstrated that the expression of CRM1 was an independent prognostic parameter for longer overall survival （95%CI, 1.27-5.39）. CONCLUSION： The prognosis of osteosarcoma is associated with the high expression of CRM1.
出处
《中华肿瘤防治杂志》
CAS
2009年第12期930-933,共4页
Chinese Journal of Cancer Prevention and Treatment
基金
上海市科委定向科研计划项目(064119637)
关键词
骨肉瘤/治疗
骨肉瘤/病理学
基因表达
预后
osteosarcoma/therapy
osteosareoma/pathology
gene expression
prognosis
